Veracyte, Inc. develops diagnostics for thyroid and non-small cell lung cancer.
The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. The company was incorporated in 2006 and is based in South San Francisco, California
Bonnie Anderson is the Co – Founder & Chief Executive Officer at Veracyte Inc.
Her career spans nearly 30 years in regulated diagnostics and life science markets where she has led both early-stage businesses, as well as mature, global enterprises. Under Ms. Andersons leadership, Veracyte has achieved significant commercialization milestones since its formation in 2008.
These include the launch of its first product; national Medicare coverage for its gene expression test; a global co-promotion partnership with Genzyme, a Sanofi company; and publication of strong clinical validation study results in the New England Journal of Medicine.
Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter, including heading the companys global cellular analysis franchise in hematology and flow cytometry.
Shelly D. Guyer is the Chief Financial Officer at Veracyte Inc.
She joined Veracyte as Chief Financial Officer in April 2013, bringing over 25 years of experience in the finance and life science industries.
Prior to Veracyte, she served as CFO and Executive Vice President of Finance and Administration at iRhythm Technologies, a medical device and services company, where she was responsible for Finance, Accounting and administrative functions.
Prior to that, she served on the management team and as Vice President of Business Development and Investor Relations at Nuvelo, a biotechnology company.
Ms. Guyer began her business career at J.P.
Karin Eastham (MBA) is the Board Member at Veracyte Inc.
Karin Eastham has been a director since December 2012. Karin currently provides consulting and executive coaching to companies in the healthcare industry in addition to serving on the boards of directors for several life science companies.
From May 2004 to September 2008, she served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research.
From 1999 to 2004, Karin served as Senior Vice President, Finance, Chief Financial Officer and Secretary of Diversa Corporation, a biotechnology company.
She previously held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company.
Samuel D. Colella (MBA) is the Board Member at Veracyte Inc.
A highly respected venture capitalist recognized for his leadership in life sciences investing, Sam Colella co – founded Versant Ventures with six other managing directors in 1999.
During the course of his career, Mr. Colella has acquired more than 20 years of successful operating experience in the high-technology industry and more than 25 years of investing experience in the health care sector. Prior to founding Versant, Mr. Colella managed one of the first life science-focused investing groups in the industry as a general partner with Institutional Venture Partners (IVP).
Previously, he was president of a New York Stock Exchange company and held a variety of functional positions in a broad array of diverse businesses, including President of Spectra-Physics, the world’s leading laser supplier, and Senior Manager of the Technical Products Division at Corning Glass.
Mr. Colella has a B.S.
Evan Jones (MBA) is the Board Director of Foundation Medicine Inc.
He is also a Board Member at Veracyte Inc.Evan Jones founded and serves as Managing Member of jVen Capital, a life sciences investment company.
Prior to that, he was cofounder, Chairman and CEO of Digene, a molecular diagnostic testing and womens health company. Mr. Jones has more than 25 years of experience in the life sciences industry, where he has initiated numerous ventures. He currently serves on the boards of OpGen (Executive Chairman), Fluidigm, CAS Medical Systems and Veracyte.
Mr. Jones also chairs the Campaign for Public Health and serves on the board of Research!America. He is a Board Member of the Childrens National Medical Center and the Childrens Research Institute where he served as Board Chair.
Mr. Jones received his B.A. from the University of Colorado.He earned his M.B.A. from The Wharton School of the University of Pennsylvania.
Mr. Colella co-founded Versant Ventures with six other Managing Directors in 1999. He has more than 20 years of operating experience in the high-technology industry and more than 25 years of investing experience in the healthcare sector.
Prior to founding Versant, Mr. Colella managed one of the first life sciences-focused investing groups as a general partner with Institutional Venture Partners (IVP).
Previously, he was President of a New York Stock Exchange company and held a variety of positions across a broad array of diverse businesses, including President of Spectra-Physics and Senior Manager of the Technical Products Division of Corning Glass. Having managed investments in medical devices, biotechnology, and health care technology companies, Mr.
Brian Atwood (MS, MBA) is the Chairman of the Board at Veracyte.
Brian Atwood specializes in biotechnology investing at Versant.
Mr. Atwood co-founded Versant Ventures after spending four years at Brentwood Venture Capital, where as a general partner he led investments in biotechnology, pharmaceuticals, and bioinformatics.
Prior to launching his career in venture capital, Mr. Atwood was founder, President, and CEO of Glycomed, where he concentrated on business development and strategic alliances, forming relationships with Eli Lilly & Company, Millipore, Genentech, and Sankyo before leading the sale of Glycomed to Ligand Pharmaceuticals.
Prior to this, he cofounded and served as Director of Perkin Elmer/Cetus Instruments, a joint venture for robotics automation and genomics research instruments and products later acquired by Perkin Elmer.
Under Mr.
Jesse I. Treu is the Board Member at Veracyte Inc.
Dr. Treu has been a Partner of Domain since its inception in 1985. He has been a director of more than 30 early-stage healthcare companies, 18 of which have so far become successful public companies.
At present, his board memberships include
Afferent Pharmaceuticals,
CoLucid Pharmaceuticals,
Regado Biosciences,
Tandem Diabetes Care and
Veracyte.
He has served as a Founder, President and Chairman of numerous venture stage companies.
Prior to the formation of Domain, Dr. Treu was vice president of the predecessor organization to The Wilkerson Group, and its venture capital arm, CW Ventures. While at CW Ventures, he served as President and CEO of Microsonics, a pioneer in computer image processing for cardiology.
Prior to that, Dr. Treu held executive positions at Technicon Instruments Corporation (now Siemens Medical Solutions Diagnostics), and at GE.
Education:
B.S.
Fred Cohen is the Board Director at XDx.
Fred Cohen (MD, PhD) is the Board Member at Veracyte Inc.
Fred Cohen is also the Managing Director at TPG and Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco.
Currently, Dr. Cohen serves on the boards of Genomic Health, xDx, FivePrime Therapeutics, Matrix Pharmaceuticals and Veracyte. He is also an investment committee member of the board of Quintiles Transnational.
Dr. Cohens academic career includes a B.S. from Yale University.An M.D. from Stanford University.A Ph.D. from Oxford University.
He is renowned for his work on protein structure and the conformational basis of prion disease.
Robert Monroe (MD), (PhD) is the Vice President, Laboratory Operations & Medical Director at Veracyte Inc.
He joined Veracyte in 2010 as the Medical Director and Vice President of Laboratory Operations.
Prior to joining Veracyte, Dr. Monroe served as the Chief Medical Officer of BioImagene (acquired by Ventana Medical Systems, a member of the Roche Group, in 2010), a leading provider of imaging solutions for anatomic pathology and clinical diagnostics. At BioImagene, Dr. Monroe led the companys efforts to develop software applications for pathologists in the areas of image analysis, telepathology, and whole slide imaging.
As the head of clinical and regulatory affairs, Dr. Monroe oversaw BioImagenes clinical collaborations with leading academic institutions as well as the clinical studies program for imaging hardware and software, culminating in multiple FDA 510(k) clearances.
Prior to joining BioImagene, Dr.
Brook Byers is the Board Director of Foundation Medicine Inc.
He has been a venture capital investor since 1972. He has been closely involved with more than fifty new technology based ventures, over half of which have already become public companies.
He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build over 110 Life Sciences companies which have already developed hundreds of products to treat major underserved medical needs for millions of patients.
Brook was the founding President and then Chairman, of four biotechnology companies which were incubated in KPCB’s offices and went on to become public companies with an aggregate market value over $8 Billion.
Chris Hall is the Chief Commercial Officer at Veracyte Inc. He joined Veracyte in 2010 as Chief Commercial Officer.
Mr. Hall most recently served as a Senior Vice President of Celera Corporation.
Prior to this, Mr. Hall held several executive positions at Berkeley HeartLab (BHL; acquired by Celera in 2007), including Chief Clinical Operations Officer and Vice President, Marketing. During his time at BHL, Mr. Hall led the commercialization of several proprietary genetic tests, as well as the launch of a new sample collection platform and was instrumental in repositioning the company from a specialty laboratory for advanced lipid blood tests to a cardiovascular disease management company.
Mr. Hall has also held management and sales positions with Asimba, Kenan Systems, Symmetrix.
Mr. Hall holds a Bachelor of Arts Degree from DePauw University in Greencastle, Indiana, and an M.B.A. from Harvard University.
Richard Lanman (MD) is the Chief Medical Officer at Veracyte Inc.
He joined Veracyte in 2008 as Chief Medical Officer.
He previously served as Executive Vice President and Chief Medical Officer of diaDexus, Inc., where he drove commercialization of PLACTM, a molecular diagnostic test for heart attack and stroke risk.
Dr. Lanman previously served as Executive Vice President of Corporate Development and Chief Medical Officer at Atherotech, an advanced cardiodiagnostics testing laboratory, where he lead clinical studies and business development.
Prior to Atherotech, Dr. Lanman was Founder and CEO of Adesso, an application service provider profiling quality and utilization for specialist physician networks.
Earlier in his career, he was in physician practice management roles as Senior Vice President and Medical Director for San Jose Medical Group, and as a Chief of Quality at Kaiser Permanente.
Giulia C. Kennedy (PhD) is the Chief Scientific Officer at Veracyte Inc.
Giulia C. Kennedy joined the company in April 2008 and serves as Chief Scientific Officer. She is also the former Senior Vice President of Research and Development at Veracyte Inc.
Prior to joining Veracyte, Dr. Kennedy led the Genomics Collaborations and Genotyping Technology R&D groups at Affymetrix, Inc.
Prior to joining Affymetrix, Dr. Kennedy was a scientific leader for the colon cancer and breast cancer gene discovery efforts at Chiron Corporation, resulting in the identification of oncology markers for therapeutic drug development.
Dr. Kennedy was previously a scientist at Millennium Pharmaceuticals, where she implemented genomic and genetic approaches to uncover diabetes susceptibility genes.
She holds a Ph.D. Degree in Biochemistry, and completed postdoctoral training at the University of California at San Francisco in the Biochemistry Department and Hormone Research Institute.
Dr.